{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T01:50:54Z","timestamp":1770688254657,"version":"3.49.0"},"reference-count":129,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Idiopathic pulmonary fibrosis represents a chronic, progressive, lethal lung disease of various etiologies exerting a dramatic impact on patients\u2019 survival and quality of life. Its increasing prevalence and high mortality rates indicate the importance of early diagnosis and management involving the assessment of specific comorbidities, such as lung cancer. Emerging evidence suggests that in the context of IPF, lung scarring may be a potential risk factor for lung cancer development. Both disease entities present pathogenic commonalities including genetic and epigenetic markers, signaling pathways and cell transformation obtaining mesenchymal phenotypes. Beyond understanding disease pathogenesis, anti-cancer drugs such as nintedanib have been successfully used to treat patients with IPF. Additionally, a therapeutic approach that includes a mix of various pleiotropic anti-fibrotic agents is currently being developed for IPF treatment. Currently, there is no consensus on the application of therapeutic algorithms in concurrent pulmonary fibrosis and lung tumors. This review summarizes the current state of knowledge on common cellular and molecular pathogenetic mechanisms of IPF and lung cancer and highlights potential therapeutic targets with fruitful results.<\/jats:p>","DOI":"10.3390\/life16020295","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:41:02Z","timestamp":1770630062000},"page":"295","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Fibrotic\u2013Cancer Continuum in IPF: Shared Mechanisms, Clinical Implications and Therapeutic Challenges"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3894-0231","authenticated-orcid":false,"given":"Panagiota","family":"Tsiri","sequence":"first","affiliation":[{"name":"Department of Internal and Respiratory Medicine, Medical School, University of Patras, 26504 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3002-9851","authenticated-orcid":false,"given":"Marousa","family":"Kouvela","sequence":"additional","affiliation":[{"name":"Oncology Unit, Third Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3889-679X","authenticated-orcid":false,"given":"Ourania","family":"Papaioannou","sequence":"additional","affiliation":[{"name":"Department of Internal and Respiratory Medicine, Medical School, University of Patras, 26504 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilina","family":"Sotiropoulou","sequence":"additional","affiliation":[{"name":"Department of Internal and Respiratory Medicine, Medical School, University of Patras, 26504 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6312-5458","authenticated-orcid":false,"given":"Matthaios","family":"Katsaras","sequence":"additional","affiliation":[{"name":"Department of Internal and Respiratory Medicine, Medical School, University of Patras, 26504 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8082-594X","authenticated-orcid":false,"given":"Nikolaos","family":"Syrigos","sequence":"additional","affiliation":[{"name":"Oncology Unit, Third Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7796-2959","authenticated-orcid":false,"given":"Fotios","family":"Sampsonas","sequence":"additional","affiliation":[{"name":"Department of Internal and Respiratory Medicine, Medical School, University of Patras, 26504 Patras, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Argyrios","family":"Tzouvelekis","sequence":"additional","affiliation":[{"name":"Department of Internal and Respiratory Medicine, Medical School, University of Patras, 26504 Patras, Greece"},{"name":"Department of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT 06511, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"King","year":"2011","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"190140","DOI":"10.1183\/16000617.0140-2019","article-title":"Chaotic activation of developmental signalling pathways drives idiopathic pulmonary fibrosis","volume":"29","author":"Froidure","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/MCP.0b013e328356b15c","article-title":"Familial forms of nonspecific interstitial pneumonia\/idiopathic pulmonary fibrosis: Clinical course and genetic background","volume":"18","author":"Borie","year":"2012","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2017.03.016","article-title":"Lung cancer in patients with idiopathic pulmonary fibrosis","volume":"45","author":"Karampitsakos","year":"2017","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S2213-2600(17)30478-2","article-title":"Patients with IPF and lung cancer: Diagnosis and management","volume":"6","author":"Tzouvelekis","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.arbres.2024.05.013","article-title":"Challenges in the Management of Lung Cancer in ILD","volume":"60","author":"Tzouvelekis","year":"2024","journal-title":"Arch. Bronconeumol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"00111-2016","DOI":"10.1183\/23120541.00111-2016","article-title":"Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis","volume":"4","author":"Kato","year":"2018","journal-title":"ERJ Open Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"220147","DOI":"10.1183\/20734735.0147-2022","article-title":"Idiopathic pulmonary fibrosis and lung cancer: Future directions and challenges","volume":"18","author":"Numan","year":"2022","journal-title":"Breathe"},{"key":"ref_9","first-page":"266","article-title":"Treatment and outcome of lung cancer in idiopathic interstitial pneumonias","volume":"31","author":"Kreuter","year":"2015","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis. Off. J. WASOG\/World Assoc. Sarcoidosis Other Granulomatous Disord."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kreuter, M., Ehlers-Tenenbaum, S., Palmowski, K., Bruhwyler, J., Oltmanns, U., Muley, T., Heussel, C.P., Warth, A., Kolb, M., and Herth, F.J. (2016). Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151425"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00432-016-2199-z","article-title":"Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival","volume":"142","author":"Kanaji","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1378\/chest.14-0359","article-title":"The impact of lung cancer on survival of idiopathic pulmonary fibrosis","volume":"147","author":"Tomassetti","year":"2015","journal-title":"Chest"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.chest.2019.06.041","article-title":"Interstitial Lung Abnormalities and Lung Cancer Risk in the National Lung Screening Trial","volume":"156","author":"Padilla","year":"2019","journal-title":"Chest"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/sj.bjc.6602061","article-title":"The epidemiology of interstitial lung disease and its association with lung cancer","volume":"91","author":"Raghu","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12931-017-0642-6","article-title":"Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis","volume":"18","author":"Karkkainen","year":"2017","journal-title":"Respir. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1183\/09031936.00077309","article-title":"Idiopathic pulmonary fibrosis: A disease with similarities and links to cancer biology","volume":"35","author":"Vancheri","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S2213-2600(17)30443-5","article-title":"Taking a giant step in the diagnosis of idiopathic pulmonary fibrosis","volume":"6","author":"Tzilas","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_18","first-page":"17","article-title":"IPF, comorbidities and management implications","volume":"32","author":"Vancheri","year":"2015","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1183\/09059180.00003613","article-title":"Common pathways in idiopathic pulmonary fibrosis and cancer","volume":"22","author":"Vancheri","year":"2013","journal-title":"Eur. Respir. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12931-017-0605-y","article-title":"Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses","volume":"18","author":"Guyard","year":"2017","journal-title":"Respir. Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Li, B., Wu, F., Ma, X., Yuan, W., Li, J., Zhang, W., and Liu, X. (2025). Pulmonary fibrosis complicated by lung cancer: Bibliometric analysis from 2004 to 2024\u2014Research status, trends and future directions. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1514831"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"00529-2020","DOI":"10.1183\/23120541.00529-2020","article-title":"The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: International survey and call for consensus","volume":"7","author":"Tzouvelekis","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.resinv.2018.03.003","article-title":"Japanese guideline for the treatment of idiopathic pulmonary fibrosis","volume":"56","author":"Homma","year":"2018","journal-title":"Respir. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20160732","DOI":"10.1259\/bjr.20160732","article-title":"A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer","volume":"90","author":"Murray","year":"2017","journal-title":"Br. J. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.crad.2017.01.005","article-title":"Lung ablation: Best practice\/results\/response assessment\/role alongside other ablative therapies","volume":"72","author":"Tselikas","year":"2017","journal-title":"Clin. Radiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Lung Cancer 2020: Epidemiology, Etiology, and Prevention","volume":"41","author":"Bade","year":"2020","journal-title":"Clin. Chest Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/1097-0142(197305)31:5<1078::AID-CNCR2820310507>3.0.CO;2-1","article-title":"Carcinoma and diffuse interstitial fibrosis of lung","volume":"31","author":"Fraire","year":"1973","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1378\/chest.108.5.1272","article-title":"Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases","volume":"108","author":"Mizushima","year":"1995","journal-title":"Chest"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.rmed.2017.06.015","article-title":"A clinicopathological study of surgically resected lung cancer in patients with usual interstitial pneumonia","volume":"129","author":"Watanabe","year":"2017","journal-title":"Respir. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000343851","article-title":"Molecular Link between Liver Fibrosis and Hepatocellular Carcinoma","volume":"2","author":"Sakurai","year":"2013","journal-title":"Liver Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1164\/rccm.201903-0511OC","article-title":"Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis","volume":"200","author":"Hobbs","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S2213-2600(13)70045-6","article-title":"Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: A genome-wide association study","volume":"1","author":"Noth","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2019.02.001","article-title":"Translational research in pulmonary fibrosis","volume":"209","author":"Mathai","year":"2019","journal-title":"Transl. Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Samarelli, A.V., Masciale, V., Aramini, B., Col\u00f3, G.P., Tonelli, R., Marchioni, A., Bruzzi, G., Gozzi, F., Andrisani, D., and Castaniere, I. (2021). Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212179"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.chest.2019.04.114","article-title":"Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer","volume":"156","author":"Tzouvelekis","year":"2019","journal-title":"Chest"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ajhg.2008.11.010","article-title":"Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer","volume":"84","author":"Wang","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/hmg\/ddw014","article-title":"Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer","volume":"25","author":"Nathan","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: A heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ballester, B., Milara, J., and Cortijo, J. (2019). Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030593"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0701009104","article-title":"Adult-onset pulmonary fibrosis caused by mutations in telomerase","volume":"104","author":"Tsakiri","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1165\/rcmb.2012-0514OC","article-title":"Telomerase and telomere length in pulmonary fibrosis","volume":"49","author":"Liu","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(14)70124-9","article-title":"Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: An observational cohort study with independent validation","volume":"2","author":"Stuart","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ajhg.2011.05.003","article-title":"A Genome-wide Association Study of Lung Cancer Identifies a Region of Chromosome 5p15 Associated with Risk for Adenocarcinoma","volume":"88","author":"Landi","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"110145","DOI":"10.18632\/oncotarget.22329","article-title":"Genetic variations in TERC and TERT genes are associated with lung cancer risk in a Chinese Han population","volume":"8","author":"Ye","year":"2017","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergencyto.2007.12.004","article-title":"Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer","volume":"182","author":"Kang","year":"2008","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/arm91050032","article-title":"Identification of Hub Genes in Idiopathic Pulmonary Fibrosis and Their Association with Lung Cancer by Bioinformatics Analysis","volume":"91","year":"2023","journal-title":"Adv. Respir. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/cncr.10708","article-title":"Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis","volume":"95","author":"Takahashi","year":"2002","journal-title":"Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1582-4934.2002.tb00188.x","article-title":"MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis","volume":"6","author":"Demopoulos","year":"2002","journal-title":"J. Cell. Mol. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cllc.2012.09.007","article-title":"KRAS mutations in lung cancer","volume":"14","author":"Karachaliou","year":"2013","journal-title":"Clin. Lung Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1753466620963015","DOI":"10.1177\/1753466620963015","article-title":"Real-life experiences in a single center: Efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients","volume":"14","author":"Feng","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S2213-2600(17)30387-9","article-title":"Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: A genome-wide association study","volume":"5","author":"Allen","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_54","first-page":"73","article-title":"Reduced transcription of the Smad4 gene during pulmonary carcinogenesis in idiopathic pulmonary fibrosis","volume":"2","author":"Takenaka","year":"2009","journal-title":"Mol. Med. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1165\/rcmb.2007-0322OC","article-title":"Thy-1 promoter hypermethylation: A novel epigenetic pathogenic mechanism in pulmonary fibrosis","volume":"39","author":"Sanders","year":"2008","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.1038\/sj.onc.1208812","article-title":"THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma","volume":"24","author":"Lung","year":"2005","journal-title":"Oncogene"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.trsl.2014.03.001","article-title":"Epigenetics of lung cancer","volume":"165","author":"Langevin","year":"2015","journal-title":"Transl. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e621","DOI":"10.1038\/cddis.2013.146","article-title":"Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts","volume":"4","author":"Huang","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2014.11.006","article-title":"Epigenetic targets for novel therapies of lung diseases","volume":"147","author":"Comer","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1084\/jem.20100035","article-title":"miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis","volume":"207","author":"Liu","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.ejca.2012.09.031","article-title":"High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer","volume":"49","author":"Yang","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.15252\/emmm.201303604","article-title":"MicroRNA mimicry blocks pulmonary fibrosis","volume":"6","author":"Montgomery","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1164\/rccm.200911-1698OC","article-title":"Inhibition and role of let-7d in idiopathic pulmonary fibrosis","volume":"182","author":"Pandit","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3810","article-title":"Targeting the TGF\u03b2 signalling pathway in disease","volume":"11","author":"Akhurst","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1381612033392341","article-title":"Re-evaluation of fibrogenic cytokines in lung fibrosis","volume":"9","author":"Kelly","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"8621","DOI":"10.1073\/pnas.1633291100","article-title":"The two faces of transforming growth factor beta in carcinogenesis","volume":"100","author":"Roberts","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1541-7786.MCR-06-0029","article-title":"Suppression of cell proliferation and signaling transduction by connective tissue growth factor in non-small cell lung cancer cells","volume":"4","author":"Chien","year":"2006","journal-title":"Mol. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Yu, J., Fu, L., Liu, Y., Li, S., Ding, Y., Li, H., Cai, C., and Wang, J. (2025). Advances and frontiers in pulmonary fibrosis and lung cancer research (2000\u20132024): A bibliometric analysis. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1596228"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nm1685","article-title":"The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak","volume":"14","author":"Tager","year":"2008","journal-title":"Nat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1158\/0008-5472.CAN-17-3797","article-title":"The Autotaxin-Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis","volume":"78","author":"Magkrioti","year":"2018","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1165\/ajrcmb.18.1.2627","article-title":"Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung","volume":"18","author":"Hancock","year":"1998","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40291-018-0355-7","article-title":"The Expression Levels of IL-4\/IL-13\/STAT6 Signaling Pathway Genes and SOCS3 Could Help to Differentiate the Histopathological Subtypes of Non-Small Cell Lung Carcinoma","volume":"22","author":"Antczak","year":"2018","journal-title":"Mol. Diagn. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"32902","DOI":"10.18632\/oncotarget.5361","article-title":"IL-13 receptor \u03b12 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice","volume":"6","author":"Xie","year":"2015","journal-title":"Oncotarget"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2004.08.040","article-title":"Wnt signaling in lung cancer","volume":"222","author":"Mazieres","year":"2005","journal-title":"Cancer Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0002-9440(10)64282-4","article-title":"Aberrant Wnt\/beta-catenin pathway activation in idiopathic pulmonary fibrosis","volume":"162","author":"Chilosi","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/labinvest.2013.6","article-title":"PI3K p110\u03b3 overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: In vitro effects of its inhibition","volume":"93","author":"Conte","year":"2013","journal-title":"Lab. Investig."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bcp.2014.05.011","article-title":"Targeting PI3K\/AKT\/mTOR pathway in non small cell lung cancer","volume":"90","author":"Fumarola","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"21114","DOI":"10.1038\/s41598-021-00717-5","article-title":"Periostin secreted by activated fibroblasts in idiopathic pulmonary fibrosis promotes tumorigenesis of non-small cell lung cancer","volume":"11","author":"Yamato","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12931-025-03294-7","article-title":"Pathogenesis and current status of the treatment of lung cancer associated with idiopathic pulmonary fibrosis","volume":"26","author":"Zhang","year":"2025","journal-title":"Respir. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/path.1295","article-title":"Expression of the developmental Sonic hedgehog (Shh) signalling pathway is up-regulated in chronic lung fibrosis and the Shh receptor patched 1 is present in circulating T lymphocytes","volume":"199","author":"Stewart","year":"2003","journal-title":"J. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Giroux-Leprieur, E., Costantini, A., Ding, V.W., and He, B. (2018). Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092835"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(12)61144-1","article-title":"New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis","volume":"380","author":"Fernandez","year":"2012","journal-title":"Lancet"},{"key":"ref_84","first-page":"3415","article-title":"Notch signaling and non-small cell lung cancer","volume":"15","author":"Zou","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12931-023-02551-x","article-title":"Expression of PD-1\/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis","volume":"24","author":"Karampitsakos","year":"2023","journal-title":"Respir. Res."},{"key":"ref_86","first-page":"e125326","article-title":"PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis","volume":"4","author":"Geng","year":"2019","journal-title":"JCI Insight"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0002-9440(10)62351-6","article-title":"Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: Potential role in idiopathic pulmonary fibrosis","volume":"166","author":"Willis","year":"2005","journal-title":"Am. J. Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.171.1.380","article-title":"Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma","volume":"171","author":"Schmidt","year":"2003","journal-title":"J. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1165\/rcmb.2009-0031OC","article-title":"Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis","volume":"43","author":"Hashimoto","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1136\/thoraxjnl-2013-203408","article-title":"Role of tetrahydrobiopterin in pulmonary vascular remodelling associated with pulmonary fibrosis","volume":"68","author":"Milara","year":"2013","journal-title":"Thorax"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.3390\/cancers7040902","article-title":"Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth","volume":"7","author":"Shiga","year":"2015","journal-title":"Cancers"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1158\/0008-5472.CAN-12-1097","article-title":"Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo","volume":"72","author":"Vicent","year":"2012","journal-title":"Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1038\/ncomms4472","article-title":"Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling","volume":"5","author":"Chen","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jtcvs.2010.11.056","article-title":"Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12\/CXCR4 axis: Role in non-small cell lung cancer tumor proliferation","volume":"141","author":"Wald","year":"2011","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2300088","DOI":"10.1183\/13993003.00088-2023","article-title":"Increased expression of CXCL6 in secretory cells drives fibroblast collagen synthesis and is associated with increased mortality in idiopathic pulmonary fibrosis","volume":"63","author":"Bahudhanapati","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.biopha.2017.11.004","article-title":"CXCL6 promotes non-small cell lung cancer cell survival and metastasis via down-regulation of miR-515-5p","volume":"97","author":"Li","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"E5618","DOI":"10.1073\/pnas.1608384113","article-title":"Pericyte-fibroblast transition promotes tumor growth and metastasis","volume":"113","author":"Hosaka","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/dvdy.24596","article-title":"Prospects for new lung cancer treatments that target EMT signaling","volume":"247","author":"Otsuki","year":"2018","journal-title":"Dev. Dyn."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ajpath.2020.09.008","article-title":"Mechanical Feed-Forward Loops Contribute to Idiopathic Pulmonary Fibrosis","volume":"191","author":"Freeberg","year":"2021","journal-title":"Am. J. Pathol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"L344","DOI":"10.1152\/ajplung.00300.2014","article-title":"Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis","volume":"308","author":"Liu","year":"2015","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"105802","DOI":"10.1016\/j.biocel.2020.105802","article-title":"The extracellular matrix and mechanotransduction in pulmonary fibrosis","volume":"126","author":"Deng","year":"2020","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41419-024-06697-4","article-title":"Modulating extracellular matrix stiffness: A strategic approach to boost cancer immunotherapy","volume":"15","author":"Mai","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Park, Y., Lee, D., Lee, J.E., Park, H.S., Jung, S.S., Park, D., Kang, D.H., Lee, S.I., Woo, S.D., and Chung, C. (2024). The Matrix Stiffness Coordinates the Cell Proliferation and PD-L1 Expression via YAP in Lung Adenocarcinoma. Cancers, 16.","DOI":"10.3390\/cancers16030598"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"151234","DOI":"10.1016\/j.ejcb.2022.151234","article-title":"Mechanical forces: The missing link between idiopathic pulmonary fibrosis and lung cancer","volume":"101","author":"Wang","year":"2022","journal-title":"Eur. J. Cell Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"C483","DOI":"10.1152\/ajpcell.00239.2023","article-title":"Senescence of alveolar epithelial progenitor cells: A critical driver of lung fibrosis","volume":"325","author":"Parimon","year":"2023","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"102315","DOI":"10.1016\/j.arr.2024.102315","article-title":"Cellular senescence in lung cancer: Molecular mechanisms and therapeutic interventions","volume":"97","author":"Jha","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41388-024-03236-5","article-title":"Senescent lung fibroblasts in idiopathic pulmonary fibrosis facilitate non-small cell lung cancer progression by secreting exosomal MMP1","volume":"44","author":"Lei","year":"2025","journal-title":"Oncogene"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1165\/rcmb.2022-0253OC","article-title":"Fibroblast-derived Extracellular Vesicles Induce Lung Cancer Progression in the Idiopathic Pulmonary Fibrosis Microenvironment","volume":"69","author":"Fujita","year":"2023","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e14229","DOI":"10.1111\/acel.14229","article-title":"A novel senolytic drug for pulmonary fibrosis: BTSA1 targets apoptosis of senescent myofibroblasts by activating BAX","volume":"23","author":"Shen","year":"2024","journal-title":"Aging Cell"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12935-023-03056-9","article-title":"Pan-cancer analysis of NFE2L2 mutations identifies a subset of lung cancers with distinct genomic and improved immunotherapy outcomes","volume":"23","author":"Wang","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3892\/ol.2022.13346","article-title":"Significant accumulation of KRAS mutations in bronchiolar metaplasia-associated honeycomb lesions of interstitial pneumonia","volume":"24","author":"Kataoka","year":"2022","journal-title":"Oncol. Lett."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00301","article-title":"Deleterious Pulmonary Surfactant System Gene Mutations in Lung Adenocarcinomas Associated With Usual Interstitial Pneumonia","volume":"2","author":"Honda","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/path.4978","article-title":"Genomic profiles of lung cancer associated with idiopathic pulmonary fibrosis","volume":"244","author":"Hwang","year":"2018","journal-title":"J. Pathol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Sampsonas, F., Bosgana, P., Bravou, V., Tzouvelekis, A., Dimitrakopoulos, F.I., and Kokkotou, E. (2024). Interstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations. Genes, 15.","DOI":"10.3390\/genes15070934"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Fujimoto, K., Ikeda, S., Tabata, E., Kaneko, T., Sagawa, S., Yamada, C., Kumagai, K., Fukushima, T., Haga, S., and Watanabe, M. (2024). KRAS(G12C) Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia. Cancers, 16.","DOI":"10.3390\/cancers16071327"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1164\/rccm.202502-0419OC","article-title":"Active Antigen-Specific Adaptive Immune Responses Are Shared among Patients with Progressive Fibrotic Interstitial Lung Disease","volume":"211","author":"Velez","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.resinv.2019.06.001","article-title":"Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia","volume":"57","author":"Ogura","year":"2019","journal-title":"Respir. Investig."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jtho.2020.08.018","article-title":"A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis","volume":"15","author":"Ikeda","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Karayama, M., Miyashita, K., Inoue, Y., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., and Inui, N. (2025). Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: A nationwide population-based study. Thorax.","DOI":"10.1136\/thorax-2025-223430"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/thoraxjnl-2021-218281","article-title":"Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis","volume":"77","author":"Naoi","year":"2022","journal-title":"Thorax"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.hrtlng.2025.08.002","article-title":"Perioperative antifibrotic therapy for patients with idiopathic pulmonary fibrosis undergoing lung cancer surgery: A systematic review and meta-analysis","volume":"74","author":"Srivali","year":"2025","journal-title":"Heart Lung"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: A subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2200380","DOI":"10.1183\/13993003.00380-2022","article-title":"Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: A randomised phase 3 trial","volume":"60","author":"Otsubo","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2016.10.011","article-title":"Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial","volume":"102","author":"Hanna","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1513\/AnnalsATS.202311-941OC","article-title":"Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis","volume":"21","author":"Ikeda","year":"2024","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.athoracsur.2016.05.094","article-title":"Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis","volume":"102","author":"Iwata","year":"2016","journal-title":"Ann. Thorac. Surg."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Mediavilla-Varela, M., Boateng, K., Noyes, D., and Antonia, S.J. (2016). The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2162-z"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/2\/295\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:58:03Z","timestamp":1770631083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/2\/295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":129,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["life16020295"],"URL":"https:\/\/doi.org\/10.3390\/life16020295","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}